tryptophan has been researched along with Hemophilia A in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belvini, D; Boon, L; Castaman, G; Chiappalupi, S; Coppola, A; Di Minno, G; Di Minno, MN; Fallarino, F; Fuchs, D; Gargaro, M; Grohmann, U; Iannitti, R; Iorio, A; Landolfi, R; Mancuso, ME; Marchesini, E; Matino, D; Mazzucconi, MG; Morfini, M; Orabona, C; Pirro, M; Puccetti, P; Radossi, P; Rocino, A; Santagostino, E; Santoro, C; Sorci, G; Tagariello, G; Talesa, VN; Tosti, A; Vacca, C; Volpi, C | 1 |
| Fletcher, BS; Liu, H; Liu, L; Mah, C | 1 |
2 other study(ies) available for tryptophan and Hemophilia A
| Article | Year |
|---|---|
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.
Topics: Animals; Case-Control Studies; Cytokines; Dendritic Cells; Drug Administration Schedule; Enzyme Induction; Factor VIII; Hemophilia A; Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Isoantibodies; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Animal; Molecular Targeted Therapy; NF-kappa B; Oligodeoxyribonucleotides; Plasma Cells; T-Lymphocytes, Regulatory; Toll-Like Receptor 9; Tryptophan | 2015 |
Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice.
Topics: Animals; Apoptosis; Autoantibodies; Blotting, Western; CD28 Antigens; Cell Line; Cells, Cultured; Factor VIII; Flow Cytometry; Gene Expression; Gene Transfer Techniques; Genetic Therapy; Hemophilia A; Immunosuppression Therapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Injections, Intravenous; Kynurenine; Liver; Mice; Plasmids; Signal Transduction; T-Lymphocytes; Transposases; Tryptophan | 2009 |